Journal of Cancer Treatment and Research

Special Issue

Individualized precise targeted therapy for non-small-cell lung cancer

  • Submission Deadline: Aug. 19, 2022
  • Status: Submission Closed
  • Lead Guest Editor: Weixiang Zhong
About This Special Issue
With the emergence of targeted drugs with different driver genes in NSCLC and the development of molecular detection technology, the diagnosis and treatment of non-small-cell lung cancer (NSCLC), which accounts for 80%-85% lung cancer, has entered the era of precision medicine.
EGFR mutation is the main target in molecular targeted therapy of NSCLC, and it is significantly related to the sensitivity of small molecule EGFR-TKIs such as gefitinib, erlotinib and osimertinib, which are widely used in the clinic and have exhibited favourable antitumour effects in the treatment of NSCLC. ALK rearrangement is the second target of concern after EGFR mutation and is also found in NSCLC. Currently, targeted therapeutic drugs for the ALK fusion gene have developed rapidly, and the clinical use of ALK-TKIs such as crizotinib, alectinib, and lorlatinib has significantly improved the survival of patients with advanced NSCLC harbouring ALK rearrangements, even better than that of EGFR-TKIs. Targeted therapy has brought revolutionary changes to the treatment of patients with EGFR, ALK, ROS1, RET, KRAS and other driver genes-mutant NSCLC. It has high efficiency and low toxicity, good treatment compliance, and significantly improves the treatment efficacy and quality of life of patients.
However, targeted therapy drugs are inevitably resistant, and overcoming drug resistance is the most serious challenge for targeted therapy. In addition, the efficacy of targeted therapy for co-mutagenic NSCLC is not good, which is another dilemma at present. More and more in-depth research is urgently needed.
The aims of the special issue entitled “Individualized precise targeted therapy for non-small-cell lung cancer” are to increase academic exchanges and cooperation and promote key advances in theory and applications in the field of targeted therapy for NSCLC, with purposes of scientifically guiding related patients and doctors towards selected, targeted drugs and ultimately achieved individualized precise therapy for NSCLC.

Keywords:

  1. Non-small-cell Lung Cancer
  2. Targeted Therapy
  3. Egfr Mutation
  4. Alk Rearrangement
  5. Ros1 Rearrangement
  6. Tyrosine Kinase Inhibitors
Lead Guest Editor
  • Weixiang Zhong

    Department of Thoracic, Guangxi Medical University, Ganzhou, China